Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
31 - 40of about 630 News
31 - 40of about 630 News
January 13, 2021
Not intended for U.S. and UK Media - Virtual Bayer Pharma Media Day:
Bayer transforms pharma business through breakthrough innovation in healthcare
READ MORE
January 12, 2021
Not intended for U.S. and UK Media
U.S. FDA grants Priority Review to New Drug Application for finerenone to treat patients with chronic kidney disease and type 2 diabetes
READ MORE
January 11, 2021
Accelerating the Transformation of Bayer:
Supervisory Board of Bayer AG appoints Sarena Lin to Board of Management as Chief Transformation and Talent Officer
READ MORE
January 07, 2021
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 4 billion euros
READ MORE
January 07, 2021
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
READ MORE
January 06, 2021
Leaps by Bayer leads USD 105 million Series B financing in Senti Bio to develop next-generation cell and gene therapies using advanced gene circuit technology platform
READ MORE
December 07, 2020
Not intended for U.S. and UK Media
Bayer and Atara Biotherapeutics enter strategic collaboration for next generation, mesothelin-targeted CAR-T cell therapies for solid tumors
READ MORE
December 02, 2020
Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation
READ MORE
December 01, 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion
READ MORE
November 17, 2020
Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease
READ MORE
31 - 40of about 630 News
31 - 40of about 630 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more